Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation of the microbiome.
Lead Product(s): Gut-Microbiome
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Rutgers University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 23, 2020
Details:
In collaboration, proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.
Lead Product(s): Gut microbiome based therapeutics
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: MRM Health
Deal Size: $15.1 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 19, 2020